Hello Future: 2020 World Young Scientist Summit to Open in Wenzhou, China
14.10.2020 14:50:00 EEST | Business Wire | Press release
2020 World Young Scientist Summit (http://www.wyss.org.cn) w ill be held in Wenzhou City of Zhejiang Province in Eastern China with the aim of gathering talents from around the world to create a better future. Leading Chinese and international scientists will communicate opinions both offline and online on innovation-related topics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005518/en/
Beidou Information Industry Base. (Photo: Business Wire)
With the theme of “The future of technology depends on the youth,” this year’s Summit has a vision to fuel the development of the community of shared future for mankind. A series of “cross-border integration" special activities will be held that focus on UN Sustainable Development Goals for 2030, the Belt and Road Initiative, the integrated development of the Yangtze River Delta, the fight against the pandemic, and youth and the future.
Moreover, the Summit will gather young talents from various industries, venture capital firms, and art circles to communicate ideas on science and technology topics. Top scientists setting the trends, young scientists getting thoroughly involved, private entrepreneurs seeking partners, and outstanding artists displaying their creativity to jointly cope with global challenges and build a more extensive platform for exchange and higher-level technology innovations.
As the Russian physiologist and Nobel laureate Ivan Petrovich Pavlov said, "The future of science has to depend on the diligent and humble young generation." The Summit expects to encourage exchanges on science and technology, promote innovation cooperation among the youth, power the economic and social development with technological innovations, and create a better future for mankind.
The Summit provides a platform for science giants to put on "roadshows" for high-end projects, for business representatives to recruit talents, and for young science and technology talents to pursue their aspirations.
Last year, 10 innovation platforms, 78 technology projects, the recruitment of 64 high-end talents and teams, and the signing of 17 strategic cooperation agreements were nailed down at the 2019 World Young Scientist Summit. Finally, the World Young Scientists Startup Park, the Summit Startup Incubation Accelerator, and a RMB 2 billion Science and Technology Innovation Fund were established at the Summit, with 12 potential projects to join the Startup Park.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005518/en/
Contact information
Xinhuanet Europe
Wei Wang
info@xinhuaeurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 15:00:00 EEST | Press release
The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical assessment for age-appropriate design and child safety – helping organizations prioritize children’s values, rights and well-being in their digital products and services. “As AI becomes part of children’s everyday lives, our responsibility as technology leaders has never been greater,” said Mary Ellen Randall, 2026 IEE
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-clinical performance of a selection of linker technology from Debiopharm’s MultiLINK™ Linker Technology suite (MLINK Select, MLINK Duo and MLINK HiSol), revealing positive implications for the development of next generation ADCs and for the future of cancer patients that require more innovative therapies to overcome their disease. Despite remarkable progress in the ADC field, many cancers remain difficult to treat due to biological complexities that challenge current-generation therapies. Tumor heterogeneity can enable cancer cells with low or absent target expression to escape treatment, while acquired resistance to single-payload ADCs may emerge over time and compr
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-breaking posters at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID 2026) in Maastricht, the Netherlands. Previously shared topline results showed the clinical trial met its primary endpoint, demonstrating pharmacokinetic (PK) comparability between TAK-881 and HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. Secondary analyses showed TAK-881 demonstrated infection outcomes and safety and tolerability profil
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors14.10.2026 14:55:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led complex cross-border transactions to strengthen balance sheets, reorganize operations and realign capital structures, both as a primary shareholder and on behalf of independent shareholders. His transa
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 14:21:00 EEST | Press release
EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into the mainland UK, which by 2027 will become its primary EV charging market. The company is building the capital base, technology and operational capability required to deliver reliable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom